Quantum Computing takes off: A look at the evolution of Quantum Technology and Patents
In 1980, the idea of a quantum processing unit was proposed. Such a processing unit doesn’t use the 1s and 0s with which we’re familiar. That “classical” way of thinking is the way we think, with a 1 for true and a 0 for false, and combinations—for example, a “false positive.” Quantum computing is based on a “superposition” of states called “quantum bits” or “qubits” for short. But there’s a big difference between the way we think and the way nature behaves.
EU Commission puts forward declaration on digital rights and principles
The European Commission is proposing to the European Parliament and Council to sign up to a declaration of rights and principles that will guide the digital transformation in the EU.
The draft declaration on digital rights and principles aims to give everyone a clear reference point about the kind of digital transformation Europe promotes and defends. It will also provide a guide for policy makers and companies when dealing with new technologies. The rights and freedoms enshrined in the EU’s legal framework, and the European values expressed by the principles, should be respected online as they are offline. Once jointly endorsed, the Declaration will also define the approach to the digital transformation which the EU will promote throughout the world.
Life Sciences: Trade Secrets and Data
Life science reporter Adam Houldsworth explains in this article that the pandemic has made it more important than ever to prevent the misappropriation of trade secrets. Pharma and biotech scientists have become more mobile and better able to access valuable information remotely and online (which has probably increased significantly this year). Complex patterns of R&D collaboration between companies and licensing also contribute to these risks, as do growing commercial incentives to find better ways to produce biosimilars. In addition, innovators need to have a strategy in place to protect the confidentiality of regulatory data following the ECJ decision and should consider this early in their R&D process. A clear data strategy on how to commercialise this in new ways is increasingly important – licensing data can save companies time and money and bring new therapies to market faster.